Other TRIUMPH Trials Additional Phase 3 trials in the TRIUMPH program are ongoing: TRIUMPH-1: Retatrutide in obesity (general population), results expected 2026 TRIUMPH-2: Retatrutide in type 2 diabetes, results expected 2026 TRIUMPH-3: Retatrutide cardiovascular outcomes trial, results expected 2027 Visualize Your Retatrutide Journey See how retatrutide builds up in your system over time and compare different dosing protocols
Advanced Multi-Compound Stacks Experienced users often combine multiple anabolic compounds to capture synergistic benefits during Retatrutide therapy
Zepbound is approved for obesity and for OSA with obesity
Your doctor will likely taper your current dose and introduce Retatrutide at a low starting amount to reduce the risk of side effects during the transition
For individuals seeking medically supervised weight management in the UK, MHRA-authorised options are available
Terrill SJ, Jackson CM, Greene HE, Lilly N, Maske CB, Vallejo S, and Williams DL